Histotripsy for Liver Cancer: Meta-Analysis and Japan's First Study

Histotripsy for liver tumors is a new local treatment that uses ultrasound focused from outside the body to break up tumor tissue mechanically, with no incision and no needle. A meta-analysis published in eClinicalMedicine in May 2026 pooled 10 studies and 553 patients and reported technical success of 94.1% with major complications of 7.0%. In Japan, a clinical study at Osaka Metropolitan University Hospital enrolled its first patient in July 2026.

Based on international papers, trial registries and US academic hospital guidance, this article explains how histotripsy differs from radiofrequency ablation, which liver cancer patients may qualify, how well tumors were controlled in studies, and where it is available in Japan, the US and Europe.

What is new: a 553-patient meta-analysis and Japan's first study

Two developments stood out this year. First, a US team (Wehrle CJ and colleagues) searched all human studies published through December 2025 and produced the first meta-analysis of histotripsy for liver tumors, published in eClinicalMedicine (vol. 95, 103926, May 2026). It combined 10 studies and 553 patients with primary liver cancer or liver metastases.

Second, human research has begun in Japan. According to the Japan Registry of Clinical Trials (jRCT), the Department of Hepatobiliary and Pancreatic Surgery at Osaka Metropolitan University Hospital registered a study of histotripsy for hepatocellular carcinoma and metastatic liver cancer in March 2026, enrolled its first patient on 6 July and last updated the record on 14 September. Gunze Medical holds exclusive distribution rights in Japan from the developer HistoSonics and is preparing for regulatory approval and insurance coverage.

What histotripsy is and how it differs from RFA

Radiofrequency ablation (RFA) and microwave ablation place a needle through the skin into the tumor and destroy it with heat. Histotripsy uses no needle. A device outside the body focuses short, intense ultrasound pulses on one point, creating a cloud of tiny bubbles that form and collapse inside the tumor, which liquefies the tumor cells. The body then absorbs the debris over the following months.

A general comparison. The actual choice depends on tumor number, size, location and liver function, as judged by the care team.

For needle-based treatment see our RFA guide and liver cancer RFA procedure and recovery; for image-guided procedures in general see the IVR guide.

Who is a candidate

Patient guidance from Johns Hopkins Medicine and Cleveland Clinic describes typical candidates as follows.

• Number and size: generally up to three tumors, each smaller than 4 cm.
• Tumor type: the US clearance covers liver tumors; studies included both hepatocellular carcinoma and metastases from cancers such as colorectal cancer.
• Patients for whom surgery is difficult: people for whom surgery, chemotherapy or radiation carries high risk or has not worked well.
• Acoustic window: ultrasound cannot pass through bone or air, so a pre-treatment ultrasound checks that the tumor can be reached.

The Osaka study enrolls patients aged 20 to under 90 with a target lesion of 3 cm or less, a Child-Pugh score of 7 or less and no extrahepatic spread or vascular invasion, with 5 participants planned.

Results: how well were tumors controlled

Key figures from human studies, as reported in the original sources.

All are single-arm studies without a control group, or analyses of such studies. "Local tumor control" means the treated tumor did not regrow at that site.

Put simply, nine out of ten treated tumors had not regrown at the treated site one year later. Many one-year study participants had advanced disease after several prior treatments, and the investigators described tumor control and survival as comparable to current standard therapies. The meta-analysis authors called histotripsy technically feasible with encouraging early clinical and radiologic results, and recommended larger multicenter studies with longer follow-up.

For results with heat-based ablation of the liver, see microwave ablation for colorectal liver metastases: one-year results in 491 European patients.

The procedure and recovery

1. Assessment: CT or MRI and ultrasound check the tumor location, the ultrasound path and liver function.
2. Anesthesia: usually general anesthesia so the patient stays still.
3. Treatment: the team locates the tumor on ultrasound and plans the zone, and the device delivers pulses to it. Johns Hopkins says treatment takes 10 to 90 minutes, with the whole visit about 1.5 to 2 hours.
4. Discharge: most patients go home the same day; some stay 24 to 48 hours.
5. Follow-up: the debris is absorbed over months, and regular imaging confirms the effect.

Cleveland Clinic notes that many people return to their routine the next day and that serious complications occur in about 1 in 100 people. Mild pain or fatigue at the treated area is usually short-lived and managed with pain relievers. Bleeding or infection is uncommon; contact the hospital promptly for fever or severe abdominal pain.

Where it is available

International patients are often not covered by a country's public insurance; confirm cost and availability directly with the hospital.

As research grows in Japan, histotripsy is expected to become another option for Japanese patients. For now, local liver cancer treatment in Japan centers on RFA and TACE; for an artery-based option see Y-90 radioembolization for liver cancer.

Questions to ask your doctor

• Can ultrasound reach my tumor without being blocked by ribs or lung?
• Is histotripsy or heat-based ablation better suited to me, and why?
• Can it be combined with chemotherapy or immunotherapy I am receiving?
• How much histotripsy experience does this hospital have, and when is the first follow-up scan?

To prepare for a consultation, see also five questions before an RFA consultation and how to check a study's phase.

Frequently asked questions

Is histotripsy the same as HIFU?

Both focus ultrasound from outside the body, but the mechanism differs. HIFU heats and burns tissue, while histotripsy uses very short pulses to create bubble clouds that break tissue apart mechanically without heat.

How long is the hospital stay?

According to US hospital guidance, most patients go home the same day and some stay 24 to 48 hours. Because general anesthesia is used, someone should accompany you home.

Can it treat liver metastases?

Yes. In the #HOPE4LIVER one-year study, 28 of 47 patients had liver metastases, most often from colorectal cancer (39.3%). Local control of all treated tumors at 12 months was 90%.

Is it available in Japan now?

It is not yet approved in Japan; a clinical study is enrolling eligible patients at Osaka Metropolitan University Hospital. It is offered as a cleared treatment in the US, Europe and Hong Kong.

Related: another non-thermal option that uses electrical pulses to break down tumour cells is covered in NanoKnife (IRE) survival results in pancreatic cancer.

This article summarizes international official sources and papers as general information and is not medical advice. Discuss treatment decisions with a doctor who has examined you.